acquired
Stage
1
Investors
About
Origo Biopharma is a pharmaceutical company focused on the research and development of organ-restricted immunotherapeutic products targeting diseases linked to TGF-β signaling, including cancer and fibrosis.
Explore Origo Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.